Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829582 | 0.96 | CYP17A1 (0.39) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL4603098 | 0.94 | GAA (0.39) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL1656241 | 0.91 | NFKB1 (0.41) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL1551115 | 0.81 | ALDH1A1 (0.40) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL28960308 | 0.81 | BTK (0.38) | NFKB1NFKB2RELABTKALDH1A1 | |
| SCHEMBL28976941 | 0.78 | TSHR (0.35) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL28167286 | 0.75 | GAA (0.38) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL18993119 | 0.73 | GAA (0.47) | NFKB1NFKB2RELACA1KMT2A | |
| SCHEMBL28797276 | 0.73 | NLRP3 (0.56) | CA2ALDH1A1 | |
| SCHEMBL5656195 | 0.73 | ATR (0.39) | CA1CA2ALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372854-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2013-02-12 | — | — | US | claimed |
| EP-2513114-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | claimed |
| US-20110294826-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2011-12-01 | — | — | US | claimed |
| WO-2011075334-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | claimed |
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2016206101-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-8372854-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2513114-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2486044-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044501-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011044503-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110294826-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010042851-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042850-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| CN-1312131-C | Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredent | DAIICHI SEIYAKU CO (JP) | 2007-04-25 | — | — | CN | disclosed |
| CN-1173971-C | Cycloalkyl-substituted aminomethylpyrrolidine derivatives | ��һ��������ҩ��ʽ���� | 2004-11-03 | — | — | CN | disclosed |
| CN-1426399-A | Process for preparing quinolone carboxylic acids and intermediates thereof | DAIICHI SEIYAKU CO (JP) | 2003-06-25 | — | — | CN | disclosed |
| CN-1422256-A | Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredent | DAIICHI SEIYAKU CO (JP) | 2003-06-04 | — | — | CN | disclosed |
| CN-1333765-A | cycloalkyl-substituted aminomethyl pyrrolidine derivatives | DAIICHI SEIYAKU CO (JP) | 2002-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294826-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | JAK3, JAK1, JAK2 | NFKB1 1390/4885NFKB2 1277/4885RELA 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.